Skip to main content
Equibles
RYTM logo

RYTM · Rhythm Pharmaceuticals, Inc. · Earnings Call Transcripts & Audio

Track RYTM — free

Use RYTM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RYTM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$95.22 -0.50 (-0.52%) At close · Sep 30
Russell 2000 member Rebalance outlook locked
Market Cap
$6.79B
Shares
68.85M
Volume · Sep 30 737.18K Avg daily vol (3M) 650.29K

Rhythm Pharmaceuticals, Inc. Earnings Call Transcripts

Quarterly earnings calls for Rhythm Pharmaceuticals, Inc. (RYTM), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲316.7% $4.28M −$40.86M '22 Q3 22-11-08 ▲383.8% $8.79M −$42.49M '22 Q4 23-03-01 ▲665.6% $11.47M −$52.18M '23 Q1 23-05-02 ▲112% $19.22M −$46.70M '23 Q2 23-08-01 ▲425.3% $22.50M −$44.16M '23 Q3 23-11-07 ▲175.7% $24.23M −$41.63M '23 Q4 24-02-22 ▲126.4% $25.97M −$141.37M '24 Q1 24-05-07 ▲51.3% $29.08M −$32.26M '24 Q2 24-08-06 ▲47.8% $33.25M −$43.64M '24 Q3 24-11-05 ▲72.6% $41.83M −$43.33M '24 Q4 25-01-10 ▲25.9% $32.70M −$49.50M '25 Q1 25-05-07 ▲66.8% $48.50M −$46.63M '25 Q2 25-08-05 ▲54.3% $51.30M −$52.90M '25 Q3 25-11-04 ▲36.9% $57.25M −$47.51M '25 Q4 26-03-16 ▲83.8% $60.11M −$55.64M '26 Q1 26-05-05 LATEST ▲46.9% $71.25M −$49.30M '26 Q2 26-08-04
Conference
Investor event
2026-09-15
Rhythm Pharmaceuticals, Inc. (RYTM) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-09
Rhythm Pharmaceuticals, Inc. (RYTM) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-08-12
Rhythm Pharmaceuticals, Inc. (RYTM) August 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-04
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2026 Earnings Call Transcript
Confident tone International expansion U.S. HO launch CHI program and pipeline expansion
Revenue
$71.25M
▲ 46.9% YoY
Diluted EPS
$-0.73
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-05
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2026 Earnings Call Transcript
Confident tone Acquired hypothalamic obesity (HO) launch U.S. commercial execution and payer access BBS base business performance
Revenue
$60.11M
▲ 83.8% YoY
Diluted EPS
$-0.83
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-16
Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2025 Earnings Call Transcript
Confident tone FDA interactions and PDUFA Bivamelagon (HO) phase 2 data and phase 3 planning EMANATE trial program (genetic indications)
Revenue
$57.25M*
▲ 36.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2025 Earnings Call Transcript
Confident tone IMCIVREE commercial growth (BBS) Acquired hypothalamic obesity (HO) launch Prader-Willi syndrome (PWS) Phase II
Revenue
$51.30M
▲ 54.3% YoY
Diluted EPS
$-0.82
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2025 Earnings Call Transcript
Confident tone BBS commercial growth (IMCIVREE) Prader-Willi development Acquired hypothalamic obesity (HO) regulatory progress
Revenue
$48.50M
▲ 66.8% YoY
Diluted EPS
$-0.75
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript
Confident tone BBS commercial performance (IMCIVREE) Phase 3 HO trial and regulatory filing Pipeline readouts (bivamelagon, PWS, RM-718)
Revenue
$32.70M
▲ 25.9% YoY
Diluted EPS
$-0.81
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-10
Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2024 Earnings Call Transcript
Confident tone Phase II Bivamelagon Trial Readout Prader-Willi Syndrome Program Bardet-Biedl Syndrome (BBS) Commercial Opportunity
Revenue
$41.83M*
▲ 72.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-05
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2024 Earnings Call Transcript
Confident tone IMCIVREE commercial execution and revenue growth DAYBREAK trial results in genetic variants of obesity International expansion and country launches
Revenue
$33.25M
▲ 47.8% YoY
Diluted EPS
$-0.73
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2024 Earnings Call Transcript
Confident tone BBS commercial execution International expansion and pricing Hypothalamic obesity Phase 3 trial
Revenue
$29.08M
▲ 51.3% YoY
Diluted EPS
$-0.55
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2024 Earnings Call Transcript
Positive tone BBS Commercial Execution International Expansion Next-Generation Pipeline
Revenue
$25.97M
▲ 126.4% YoY
Diluted EPS
$-2.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2023 Earnings Call Transcript
Confident tone U.S. commercial performance and BBS launch Hypothalamic obesity Phase 3 trial International expansion (Europe)
Revenue
$24.23M*
▲ 175.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2023 Earnings Call Transcript
Revenue
$22.50M
▲ 425.3% YoY
Diluted EPS
$-0.76
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2023 Earnings Call Transcript
Revenue
$19.22M
▲ 112% YoY
Diluted EPS
$-0.82
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2023 Earnings Call Transcript
Revenue
$11.47M
▲ 665.6% YoY
Diluted EPS
$-0.92
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-01
Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2022 Earnings Call Transcript
Revenue
$8.79M*
▲ 383.8% YoY
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2022 Earnings Call Transcript
Revenue
$4.28M
▲ 316.7% YoY
Diluted EPS
$-0.79
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2022 Earnings Call Transcript
Revenue
$9.07M
▲ 3208.8% YoY
Diluted EPS
$-0.89
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2022 Earnings Call Transcript
Revenue
$1.50M
▲ 4180% YoY
Diluted EPS
$-1.05
▼ 216.7% YoY
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2021 Earnings Call Transcript
Revenue
$1.82M*
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2021 Earnings Call Transcript
Revenue
$1.03M
Diluted EPS
$-0.70
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2021 Earnings Call Transcript
Revenue
$274,000
Diluted EPS
$-0.70
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–24 of 24 earnings calls
Key facts CIK 1649904 CUSIP 76243J105 13F (30d) 9 filings 9 filers Visit website Investor relations